{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T11:55:56Z","timestamp":1782129356134,"version":"3.54.5"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T00:00:00Z","timestamp":1697068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Primary urethral carcinoma (PUC) has a low incidence, but with high aggressiveness. Most of the patients are found in late stage, with poor prognosis. At present, chemotherapy is still the main treatment for metastatic PUC, but it has limited effect. Here, we report a case of metastatic PUC with low HER2 expression that developed disease progression after multiline therapy including chemotherapy, programmed death-1 (PD-1) inhibitors and multi-targeted receptor tyrosine kinase (RTK) inhibitor. After receiving Disitamab Vedotin(a novel antibody drug conjugate, ADC) and toripalimab (a PD-1 inhibitor), the patient achieved persistent PR, and the PFS exceeded 12 months up to now. Our report indicates that, despite the patient of metastatic PUC has low expression of HER2, it is still possible to benefit from Disitamab Vedotin combined with PD-1 inhibitor, which may reverse the drug resistance of PD-1 inhibitor and chemotherapy to a certain extent. But larger sample studies are needed to determine the efficacy of this treatment strategy and its impact on survival.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1254812","type":"journal-article","created":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T12:40:49Z","timestamp":1697114449000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Disitamab Vedotin plus anti-PD-1 antibody show good efficacy in refractory primary urethral cancer with low HER2 expression: a case report"],"prefix":"10.3389","volume":"14","author":[{"given":"Yue","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin-Yin","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Qin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Ping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2019.07.001","article-title":"Current disease management of primary urethral carcinoma","volume":"5","author":"Janisch","year":"2019","journal-title":"Eur Urol Focus"},{"key":"B2","doi-asserted-by":"crossref","DOI":"10.1046\/j.1464-410X.1998.00878.x","article-title":"Female urethral carcinoma: an analysis of treatment outcome and a plea for a standardized management strategy","volume":"82","author":"Dalbagni","year":"1998","journal-title":"Br J Urol"},{"key":"B3","doi-asserted-by":"crossref","DOI":"10.1016\/j.urology.2006.08.1057","article-title":"Incidence of primary urethral carcinoma in the United States","volume":"68","author":"Swartz","year":"2006","journal-title":"Urology"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2020.06.003","article-title":"European association of urology guidelines on primary urethral carcinoma-2020 update","volume":"3","author":"Gakis","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"B5","doi-asserted-by":"crossref","DOI":"10.1016\/S1078-1439(03)00174-1","article-title":"Surgical treatment for local control of female urethral carcinoma","volume":"22","author":"Dimarco","year":"2004","journal-title":"Urol Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2023.02.011","article-title":"Reprint of: Female Urethral Carcinoma: A contemporary review of the clinicopathologic features, with emphasis on the histo-anatomic landmarks and potential staging issues","volume":"133","author":"Lagarde-Lenon","year":"2023","journal-title":"Hum Pathol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.10.031","article-title":"Incidence and survival of rare urogenital cancers in Europe","volume":"48","author":"Visser","year":"2012","journal-title":"Eur J Cancer (Oxford England: 1990)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2016.09.042","article-title":"Outcomes and prognostic factors of primary urethral cancer","volume":"100","author":"Sui","year":"2017","journal-title":"Urology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-015-1583-7","article-title":"Prognostic factors and outcomes in primary urethral cancer: results from the international collaboration on primary urethral carcinoma","volume":"34","author":"Gakis","year":"2016","journal-title":"World J Urol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2018.05.012","article-title":"Survival outcomes associated with female primary urethral carcinoma: review of a single institutional experience","volume":"16","author":"Peyton","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/jso.26790","article-title":"Clinical features and oncological outcomes of primary female urethral cancer","volume":"125","author":"Lee","year":"2022","journal-title":"J Surg Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/1078-0432.CCR-20-2488","article-title":"Open-label, multicenter, phase II study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma","volume":"27","author":"Sheng","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.asjsur.2022.01.014","article-title":"Treatment and outcomes of primary urethral cancer","volume":"45","author":"Yang","year":"2022","journal-title":"Asian J Surg"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2018.06.007","article-title":"Optimizing the role of surgery and radiation therapy in urethral cancer based on histology and disease extent","volume":"102","author":"Son","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30030-4","article-title":"Antibody-drug conjugates for cancer therapy","volume":"17","author":"Thomas","year":"2016","journal-title":"Lancet Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2022.2069883","article-title":"Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy","volume":"29","author":"Shi","year":"2022","journal-title":"Drug Deliv"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202012_24196","article-title":"Conjugating MMAE to a novel anti-HER2 antibody for selective targeted delivery","volume":"24","author":"Li","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-021-01168-7","article-title":"Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors","volume":"24","author":"Xu","year":"2021","journal-title":"Gastric Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s10549-021-06384-4","article-title":"A HER2 target antibody drug conjugate combined with anti-PD-(L)1 treatment eliminates hHER2+\u2009tumors in hPD-1 transgenic mouse model and contributes immune memory formation","volume":"191","author":"Huang","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.6_suppl.515","article-title":"Study RC48-C014: Preliminary results of RC48-ADC combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma","volume":"40","author":"Zhou","year":"2022"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-023-03419-1","article-title":"HER2-targeting antibody-drug conjugate RC48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study","author":"Chen","year":"2023","journal-title":"Cancer Immunol Immunother"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1254812\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T12:40:56Z","timestamp":1697114456000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1254812\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,12]]},"references-count":21,"alternative-id":["10.3389\/fimmu.2023.1254812"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1254812","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,12]]},"article-number":"1254812"}}